Zelluna Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 7

  • Investments
  • 3

Zelluna General Information

Description

Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the development of T-Cell Receptor Natural Killer cell therapies for the treatment of solid cancers. The company's current pipeline consists of allogeneic TCR-NK R&D programs ZI-MA4-1, ZI-KL1-1, and ZI-PR-1 targeting well validated antigens expressed across a broad range of solid tumors.

Contact Information

Website
www.ultimovacs.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Ullernchausseen 64
  • 0379 Oslo
  • Norway
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Zelluna Immunotherapy
Vertical(s)
Life Sciences, Oncology
Former Stock Listing
ZLNA
Corporate Office
  • Ullernchausseen 64
  • 0379 Oslo
  • Norway

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zelluna Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zelluna‘s full profile, request access.

Request a free trial

Zelluna Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the developmen
Drug Discovery
Oslo, Norway
20 As of 2024

Tuebingen, Germany
 

Oslo, Norway
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zelluna Competitors (11)

One of Zelluna’s 11 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Formerly VC-backed Tuebingen, Germany
Zelluna Immunotherapy Formerly VC-backed Oslo, Norway
BioNTech Formerly VC-backed Mainz, Germany
Agenus Formerly VC-backed Lexington, MA
American Gene Technologies Venture Capital-Backed Rockville, MD
You’re viewing 5 of 11 competitors. Get the full list »

Zelluna Patents

  • 27

    Total Documents Applications and Grants

  • Total Patents Families

  • 21

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Zelluna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017275782-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016
JP-2022171684-A Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016
US-20190247482-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016
EP-3463436-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016
CA-3026172-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 A61K39/0011
To view Zelluna’s complete patent history, request access »

Zelluna Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zelluna Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zelluna‘s full profile, request access.

Request a free trial

Zelluna Investments & Acquisitions (3)

Zelluna’s most recent deal was a Reverse Merger with Zelluna Immunotherapy. The deal was made on 17-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zelluna Immunotherapy 17-Dec-2024 Reverse Merger Drug Discovery
Affyn 30-Jan-2022 Early Stage VC Entertainment Software
Immuneed 11-Jul-2018 Buyout/LBO Drug Discovery
To view Zelluna’s complete investments and acquisitions history, request access »

Zelluna Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Immuneed Uppsala, Sweden 2014

Zelluna FAQs

  • When was Zelluna founded?

    Zelluna was founded in 2011.

  • Where is Zelluna headquartered?

    Zelluna is headquartered in Oslo, Norway.

  • What is the size of Zelluna?

    Zelluna has 20 total employees.

  • What industry is Zelluna in?

    Zelluna’s primary industry is Drug Discovery.

  • Is Zelluna a private or public company?

    Zelluna is a Private company.

  • What is Zelluna’s current revenue?

    The current revenue for Zelluna is .

  • How much funding has Zelluna raised over time?

    Zelluna has raised $104M.

  • Who are Zelluna’s investors?

    Canica, Gjelsten Holding, Inven2, Langøya Invest, and Radforsk Investeringsstiftelse are 5 of 8 investors who have invested in Zelluna.

  • Who are Zelluna’s competitors?

    Immatics, Zelluna Immunotherapy, BioNTech, Agenus, and American Gene Technologies are some of the 11 competitors of Zelluna.

  • When was Zelluna acquired?

    Zelluna was acquired on 17-Dec-2024.

  • Who acquired Zelluna?

    Zelluna was acquired by Zelluna Immunotherapy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »